GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Book Value per Share

Vascular Biogenics (Vascular Biogenics) Book Value per Share : $0.27 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Book Value per Share?

Vascular Biogenics's book value per share for the quarter that ended in Jun. 2023 was $0.27.

During the past 12 months, Vascular Biogenics's average Book Value Per Share Growth Rate was -45.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -31.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -27.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Vascular Biogenics was 14.00% per year. The lowest was -31.50% per year. And the median was -14.00% per year.

Vascular Biogenics's current price is $0.155. Its book value per share for the quarter that ended in Jun. 2023 was $0.27. Hence, today's PB Ratio of Vascular Biogenics is 0.57.

During the past 11 years, the highest P/B Ratio of Vascular Biogenics was 4.44. The lowest was 0.31. And the median was 1.27.


Vascular Biogenics Book Value per Share Historical Data

The historical data trend for Vascular Biogenics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Book Value per Share Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.48 1.00 0.64 0.75 0.32

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.36 0.32 0.29 0.27

Competitive Comparison of Vascular Biogenics's Book Value per Share

For the Biotechnology subindustry, Vascular Biogenics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's PB Ratio falls into.



Vascular Biogenics Book Value per Share Calculation

Vascular Biogenics's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(22.45-0.00)/69.75
=0.32

Vascular Biogenics's Book Value Per Share for the quarter that ended in Jun. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(19.24-0.00)/70.50
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Vascular Biogenics  (NAS:VBLT) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Vascular Biogenics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142